Recent research have focused on the intersection of GLP|GIP|GCGR stimulant therapies and DA communication. While GIP agonists are widely employed for addressing type 2 diabetes, their potential consequences on reinforcement circuits, specifically mediated by dopamine networks, are gaining signifi